Unfazed by disruptions, Cowen's investment arm backs AM-Pharma's $176M pivotal plan around lethal condition
It may not be the best time to start up a late-stage study unrelated to Covid-19, but AM-Pharma isn’t letting a slight delay derail its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
